Commerce Bank Raises Position in Moderna, Inc. (NASDAQ:MRNA)

Commerce Bank lifted its stake in Moderna, Inc. (NASDAQ:MRNA) by 9.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,471 shares of the company’s stock after purchasing an additional 787 shares during the quarter. Commerce Bank’s holdings in Moderna were worth $633,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC bought a new stake in Moderna in the second quarter worth $26,000. Family Firm Inc. purchased a new stake in shares of Moderna in the second quarter valued at $33,000. Bank & Trust Co purchased a new stake in shares of Moderna in the second quarter valued at $36,000. Hanseatic Management Services Inc. bought a new stake in shares of Moderna in the 2nd quarter worth about $48,000. Finally, Plato Investment Management Ltd boosted its stake in shares of Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after purchasing an additional 288 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

MRNA has been the topic of a number of recent analyst reports. Oppenheimer lowered shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a report on Thursday, September 19th. UBS Group dropped their price objective on Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Bank of America cut their price objective on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research report on Friday, September 13th. Finally, Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and decreased their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $84.00.

Moderna Trading Up 6.2 %

MRNA opened at $43.66 on Tuesday. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm has a market cap of $16.80 billion, a price-to-earnings ratio of -7.50 and a beta of 1.69. Moderna, Inc. has a 12 month low of $35.80 and a 12 month high of $170.47. The stock has a fifty day moving average price of $54.96 and a 200-day moving average price of $93.71.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the previous year, the company posted ($1.39) earnings per share. The firm’s revenue was up 3.8% on a year-over-year basis. As a group, equities research analysts anticipate that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 7.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold 2,930 shares of company stock valued at $217,170 over the last 90 days. Insiders own 15.20% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.